

References

1. Michael H. Crawford, Current Diagnosis & Treatment of Cardiology 2nd edition 2003, pages 283,284.
2. Topol & Marso manual of cardiovascular Medicine 2nd Edition 2004, pages 284-28
3. Allessie's MA Konings KT Kirchhof CJ: Mapping of atrial fibrillation Mechanisms & Therapeutic Strategies. Armonk NY: Futura Pub, 1994:37.
4. Levy S: Classification system of atrial fibrillation. Curr Opin Cardiol 2000; 15:5
5. Aryl L. Goldberger Clinical ECG; 6th edition 1999, pages 158,159
6. Mark E. Josephson & Peter Zimetbaum, volume 3, chapter 8, section 2, A.F, Harrison's principle of Internal Medicine,McGraw-Hill, 15th Edition, 2001, Page 1295.
7. Volume Diseases of cardiovascular System 2001, page 1295
7American heart association, Eric N.Prystowsky MD, Chair. Circulation 1996; 93:1262-1277.
8. John P. DiMarco, Bernard J. Gersh & Lionel H. Opie, chapter 8, antiarrhythmic drugs & strategies, Lionel H. Opie, Drugs for the Heart, Elsevier Saunders, 6th edition, 2005, pages 218-274.
9. Staff members of the department of Pharmacology & Therapeutics Benha Faculty of medicine New Trends in Pharmacological & Therapeutics (NTPAT) 2002-2003 Pages 148 & 152.
10. Feinberg WM, Blackshear JL, Laupacis A, Kronmal R, Hart RG. Prevalence, age distribution, and gender of patients with atrial fibrillation. Analysis and implications. Arch Intern Med 1995; 155:469.
11. Mahoney, Feinberg WM, Blackshear JL, Laupacis A, Kronmal R, Hart RG. Prevalence, age distribution, and gender of patients with atrial fibrillation. Analysis and implications. Arch Intern Med 2002;155:469
12. Kitzman ,Kannel WB, Wolf PA, Benjamin EJ, Levy D. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol 1998; 82:2N-9N.

13. Aranki G, Sheetal Ladv (28/06/2006). NICE and BHS launch updated hypertension guideline. National Institute for Health and Clinical Excellence. Retrieved on 2006-09-30.
14. Pehkonen, Perez-Llamas, F, *J Hum Nutr Diet*, Dec 1996, 9:6:463-471
15. Almassi, Boutjdir M, et al. Inhomogeneity of cellular refractoriness in human atrium: factor or arrhythmia ? *PACE* 1986; 9(II):1095-1100
16. Frustaci A, Chimenti C, Bellocci F, Morgante E, Russo MA, Maseri A. Histological substrate of atrial biopsies in patients with lone atrial fibrillation. *Circulation* 1997; 96:1180-4
17. Boutjdir M, Inhomogeneity of cellular refractoriness in human atrium: factor or arrhythmia? *PACE* 1986; 9(II):1095-1100
18. Attuel P, Failure in the rate adaptation of the atrial refractory periods: new parameter to assess atrial vulnerability. *PACE* 1984; 7:1382
19. Nattel S, Electrophysiological remodeling: are ion channel static players or dynamic movers? *J Cardiovasc Electrophysiol* 1999; 10:1553-1556
20. Nattel S, atrial electrophysiological remodeling caused by rapid atrial activation: underlying mechanisms and clinical relevance to atrial fibrillation. *Cardiovasc Res* 1999; 42:298-308
21. Van Wagoner, Atrial L-type Ca^{++} currents and human atrial fibrillation. *Circ Res* 1999; 85:428-436
22. Yue L, Ionic remodeling underlying action potential changes in a canine model of atrial fibrillation. *Circ Res* 1997; 81:512-525
23. Yue L, Molecular mechanisms underlying ionic remodeling in a dog model of atrial fibrillation. *Circ Res* 1999; 84:776-784
24. Biffi M, Electrophysiological effects of flecainide and propafenone on atrial fibrillation cycle and relationship with arrhythmia termination. *Heart* 1999; 82:176-182
25. Biffi M, Atrial fibrillation recurrence after internal cardioversion: prognostic importance of electrophysiologic parameters. *Heart* 2002; 87:443-448
26. Manios EG, Changes in atrial electrical properties following cardioversion of chronic atrial fibrillation: relation with recurrence. *Cardiovascular Research* 2000; 47:244-253
27. Tieleman RG, Verapamil reduces tachycardia-induced electrical remodeling of the atria. *Circulation* 1997; 95:1945-53

28. Lee SH, Effect of verapamil on long term tachycardia-induced atrial electrical remodeling. *Circulation* 2000; 101:200-206
29. Gaspo R, Functional mechanisms underlying tachycardia-induced sustained atrial fibrillation in a chronic dog model. *Circulation* 1997;96:4027-35
30. Fareh S, the T-type Ca^{2+} channel blocker mibefradil prevents the development of a substrate for atrial fibrillation by tachycardia-induced atrial remodeling in dogs. *Circulation* 1999; 100:2191-97
31. Fareh S, Differential efficacy of L- and T-type calcium channel blockers in preventing tachycardia-induced remodeling in dogs. *Cardiovasc Res* 2001; 49:762-770
32. Pogwizd SM, Upregulation of $\text{Na}^{+}/\text{Ca}^{++}$ exchanger expression and function in an arrhythmogenic rabbit model of heart failure *Circ Res* 1999;85:1009-1019
33. Hobai IA, Enhanced Ca^{++} -activated Na^{+} - Ca^{++} exchange activity in canine pacing-induced heart failure *Circ Res* 2000;87:690-698
34. Pogwizd SM, Arrhythmogenesis and contractile dysfunction in heart failure: roles of sodium-calcium exchange, inward rectifier potassium current and residual beta-adrenergic responsiveness. *Circ Res* 2001; 88:1159-67
35. (Danshi Li, Effects of experimental heart failure on atrial cellular and ionic electrophysiology. *Circulation* 2000; 101:2631-38)
36. Shinigawa K, Dynamic nature of atrial fibrillation substrate during development and reversal of heart failure in dogs. *Circulation* 2002;105:2672-78
37. Danshi Li, Effects of angiotensin-converting enzyme inhibition on the development of the atrial fibrillation substrate in dogs with ventricular tachypacing-induced congestive heart failure. *Circulation* 2001;104:2608-14
38. Natale A, Newby KH, Pisano E et al. Prospective randomized comparison of antiarrhythmic therapy versus first-line radiofrequency ablation in patients with atrial flutter. *J Am Coll Cardiol* 2000; 35:1898-904.
39. Prystowsky EN, Benson DW, Jr., Fuster V, Management of patients with atrial fibrillation. A Statement for Healthcare Professionals. From the Subcommittee on Electrocardiography and Electrophysiology, American Heart Association. *Circulation* 1996; 93:1262-77.).

40. Shinbane JS, Wood MA, Jensen DN, Ellenbogen KA, Fitzpatrick AP, Scheinman MM. Tachycardia-induced cardiomyopathy: a review of animal models and clinical studies. *J Am Coll Cardiol* 1997; 29:709-15
41. Packer DL, Bardy GH, Worley SJ. Tachycardia-induced cardiomyopathy: a reversible form of left ventricular dysfunction. *Am J Cardiol* 1986; 57:563-70
42. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials [published erratum appears in *Arch Intern Med* 1994 Oct 10; 154(19):2254]. *Arch Intern Med* 1994; 154:1449-57
43. Asinger RW, Koehler J, Pearce LA. Pathophysiologic correlates of thromboembolism in nonvalvular atrial fibrillation: II. Dense spontaneous echocardiographic contrast (The Stroke Prevention in Atrial Fibrillation [SPAF-III] study). *J Am Soc Echocardiogr* 1999; 12:1088-96
44. A-fib 101
45. NHLBI's Framingham Heart Study Article Date: 16 Jun 2004 - (UK)
46. Ridker PM, Hennekens CH, Buring JE, et al. C-reactive protein and other Markers of inflammation in the prediction of cardiovascular Disease. *N Engl J Med*. 2000; 342:836–843.
47. Mihm MJ, Yu F, Carnes CA,. Impaired myofibrillar energetics and Oxidative injury during human atrial fibrillation. *Circulation*. 2001; 104: 174–180.
48. Patients with nonvalvular atrial fibrillation at low risk of stroke during treatment with aspirin: Stroke Prevention in Atrial Fibrillation III Study. The SPAF III Writing Committee for the Stroke Prevention in Atrial Fibrillation Investigators [see comments]. *JAMA* 1998; 279:1273-7.
49. Fuster , ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation *JACC* Vol.38, August 2001:1231-65
50. *JACC* Vol.38, August 2001:1231-65
51. Fuster V, Ryden LE, Asinger RW. ACC/AHA/ESC guidelines for the management of patients with AF: executive summary. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients with Atrial Fibrillation: developed in Collaboration with the North

- American Society of Pacing and Electrophysiology. *J Am Coll Cardiol.* 2001; 38:1231-1266.)
52. Fuster V, Rydén LE. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation. *Eur Heart J* 2001; 22: 1852–1923
 53. Pelosi F Jr, Morady F. Evaluation and management of atrial fibrillation. *Med Clin North Am* 2001; 85:225–44.
 54. Carlsson J, Neuzner J, Rosenberg YD. Therapy of atrial fibrillation: rhythm control versus rate control. *PACE* 2000; 23:891–903.
 55. Hohnloser SH, Kuck KH, Lilienthal J. Rhythm or rate control in atrial Fibrillation. Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomised trial. *Lancet* 2000; 356:1789–94.
 56. Texas Heart Institute's Sixth Symposium on Cardiac Arrhythmias: New Pharmacologic and Interventional Strategies; held at the Houstonian Hotel, Club & Spa; 19 February 2005; Houston
 57. Klein AL, Murray RD, Grimm RA. Role of transesophageal echocardiography- Guided cardioversion of patients with atrial fibrillation. *J Am Coll Cardiol.* 2001; 37:691-704. [PMID: 11693739]
 58. Klein AL, Grimm RA, Murray RD, Apperson-Hansen C, Asinger RW, Black IW. Use of transesophageal echocardiography to guide cardioversion in patients With atrial fibrillation. *N Engl J Med.* 2001; 344:1411-20. [PMID: 11346805]
 59. Zehender M, Hohnloser S, Mu¨ller B, Meinertz T, Just H. Effects of amiodarone versus quinidine and verapamil in patients with chronic atrial fibrillation: results of a comparative study and a 2-year follow-up. *J Am Coll Cardiol.* 1992; 19:1054-9. [PMID: 1552095]
 60. Stambler BS, Wood MA, Ellenbogen KA, Perry KT, Wakefield LK, VanderLugt JT. Efficacy and safety of repeated intravenous doses of ibutilide for rapid Conversion of atrial flutter or fibrillation. Ibutilide Repeat Dose Study Investigators. *Circulation.* 1996; 94:1613-21. [PMID: 8840852]
 61. Stroobandt R, Stiels B, Hoebrechts R. Propafenone for conversion and prophylaxis of atrial fibrillation. Propafenone Atrial Fibrillation Trial Investigators *Am J Cardiol.* 1997;79:418-23. [PMID: 9052343]
 62. Bellandi F, Cantini F, Pedone T, Palchetti R, Bamoshmoosh M, Dabizzi RP. Effectiveness of intravenous propafenone for conversion of recent-onset atrial fibrillation: a placebo-controlled study. *Clin Cardiol.* 1995; 18:631-4. [PMID: 8590531]

63. Tommaso C, McDonough T, Parker M, Talano JV. Atrial fibrillation and flutter immediate control and conversion with intravenously administered verapamil. *Arch Intern Med.* 1983; 143:877-81. [PMID: 6679229]
64. Kingma JH, Suttrop MJ. Acute pharmacologic conversion of atrial fibrillation and flutter: the role of flecainide, propafenone, and verapamil. *Am J Cardiol.* 1992; 70:56A-60A. [PMID: 1510000]
65. Kerr CR, Talajic M, Connolly SJ. Recurrence of Atrial Fibrillation Following Its Initial Diagnosis: Follow-Up of the Canadian Registry of Atrial Fibrillation [abstr]. *Circulation* 1999; 100: I-286.
66. Hohnloser SH, Kuck KH. Atrial fibrillation--maintaining sinus rhythm versus ventricular rate control: the PIAF trial. *Pharmacological Intervention in Atrial Fibrillation. J Cardiovasc Electrophysiol* 1998; 9:S121-S126.
67. Prystowsky EN, Benson DW, Jr., Fuster V . Management of patients with atrial fibrillation. A Statement for Healthcare Professionals. From the Subcommittee on Electrocardiography and Electrophysiology, American Heart Association. *Circulation* 1996; 93:1262-77.
68. Goethals P, Debruyne P, Saffarian M. Drug-induced Brugada syndrome. *Acta Cardiol* 1998; 53:157-60.
69. Hohnloser SH, Kuck KH. Atrial fibrillation--maintaining sinus rhythm versus ventricular rate control: the PIAF trial. *Pharmacological Intervention in Atrial Fibrillation. J Cardiovasc Electrophysiol* 1998; 9:S121-S126.
70. Matana a, Goldner V, Stanic K, Mavric Z, Zaputovic L, Matana Z. Unmasking effect of propafenone on the concealed form of the Brugada phenomenon. *Pacing Clin Electrophysiol* 2000; 23:416-8.
71. Van Gelder IC, Tuinenburg AE, Schoonderwoerd BS, Tieleman RG, Crijns HJ Pharmacologic. versus direct-current electrical cardioversion of atrial flutter and fibrillation. *Am J Cardiol* 1999; 84:147R-51R.
72. ACC/AHA/ESC GUIDELINES FOR THE MANAGEMENT OF PATIENTS WITH ATRIAL FIBRILLATION JACC Vol.38, August 2001:1231-65
73. Vardas PE, Kochiadakis GE, Igoumenidis NE, Tsatsakis AM, Simantirakis EN, Chlouverakis GI. Amiodarone as a first-choice drug for restoring sinus Rhythm in patients with atrial fibrillation: a randomized, controlled study. *Chest.* 2000; 117:1538-45. [PMID: 10858380]

74. Tieleman RG, Van Gelder IC, Crijns HJ. Early recurrences of atrial fibrillation after electrical cardioversion: a result of fibrillation-induced electrical remodeling of the atria? *J Am Coll Cardiol* 1998; 31:167-73.
75. Kuhlkamp V, Schirdewan A, Stangl K, Homberg M, Ploch M, Beck OA. Use of metoprolol CR/XL to maintain sinus rhythm after conversion from persistent atrial fibrillation: a randomized, double-blind, placebo-controlled study [see comments]. *J Am Coll Cardiol* 2000; 36:139-46.
76. Kuhlkamp V, Schirdewan A, Stangl K, Homberg M, Ploch M, Beck OA. Use of metoprolol CR/XL to maintain sinus rhythm after conversion from persistent atrial fibrillation: a randomized, double-blind, placebo-controlled study [see comments]. *J Am Coll Cardiol* 2000; 36:139-46.
77. Favale S, Pappone C, Nacci F, Fino F, Resta F, Dicandia CD. Sudden death due To atrial fibrillation in hypertrophic cardiomyopathy: a predictable event in a Young patient. *Pacing Clin Electrophysiol* 2003; 26:637-9.
78. Wyse DG, Waldo AL, DiMarco JP, Domanski MJ, Rosenberg Y, Schron EB, Kellen JC, Greene HL, Mickel MC, Dalquist JE, Corley SD. A comparison of rate control and rhythm control in patients with atrial fibrillation. *N Engl J Med*. 2002; 347:1825-33
79. Peters NS, Schilling RJ, Kanagaratnam P, Markides V. Atrial fibrillation: Strategies to control, combat and cure. *Lancet*. 2002; 359:593-603.
80. Verma A, Newman D, Geist M, Greenhut S, Laslop J, DeBellis L, Freeman MR, Dorian P. Effects of rhythm regularization and rate control in improving left ventricular function in atrial fibrillation patients undergoing atrioventricular nodal ablation. *Can J Cardiol*. 2001; 17:437-45.
81. Falk RH. Atrial Fibrillation. *N Engl J Med*. 2001; 344:1067-78.
82. Levy T, Walker S, Mason M, Spurrell P, Rex S, Brant S, Paul V. Importance of rate control or rate regulation for improving exercise capacity and quality of life in patients with permanent atrial fibrillation and normal left ventricular function: a randomised controlled study. *Heart*. 2001; 85:171-8.
83. Segal JB, McNamara RL, Miller MR, Kim N, Goodman SN, Powe NR, Robinson K, Yu D, Bass EB. The evidence regarding the drugs used for ventricular rate control. *J Fam Pract*. 2000 Jan; 49(1):47-59.

84. Olshansky B, Warner A, Solomon A, Sharma A, Platia E, O'Neill G, Feld G, L, Rosenfeld Akiyama T, Brodsky M, Ingalls S, Greene HL, NHLBI AFFIRM Investigators. Rate Control in Atrial Fibrillation: A Substudy of the AFFIRM Trial. **In press**
85. Farshi R, Kistner D, Sarma JS, Longmate JA, Singh BN. Ventricular rate control in chronic atrial fibrillation during daily activity and programmed exercise: a crossover open-label study of five drug regimens. *J Am Coll Cardiol*. 1999; 33:304-10.
86. Verma A, Newman D, Geist M, Greenhut S, Laslop J, DeBellis L, Freeman MR, Dorian P. Effects of rhythm regularization and rate control in improving left Ventricular function in atrial fibrillation patients undergoing atrioventricular nodal ablation. *Can J Cardiol*. 2001; 17:437-45.
87. Grogan M, Smith HC, Gersh BJ, Wood DL. Left ventricular dysfunction due to atrial fibrillation in patients initially believed to have idiopathic dilated cardiomyopathy. *Am J Cardiol*. 1992;69:1570-3.
88. Pinter A, Dorian P, Paquette M, Ng A, Burns M, Spanu I, Freeman M, Korley V, Newman D. Left Ventricular Performance During Acute Rate Control in Atrial Fibrillation: The Importance of Heart Rate and Agent Used. *J Cardiovasc Pharmacol Therapeut* 2003;8:17-24.
89. Dorian P, Philippon F, Gardner MJ, Talajic M, Sterns L. A Randomized Pilot Study of Pacing and Ablation vs. Rate Control. *Can J Cardiol* 2003;19:229A
90. Wood, MA, Brown-Mahoney C, Kay N, Ellenbogen K. Clinical Outcomes After Ablation and Pacing Therapy for Atrial Fibrillation. A Meta-Analysis. 2000; 101:1138-44.
91. Doshi R, Daoud E, Fellows C, Turk K, Duran A, Hamdan M. PAVE: The first prospective randomized study evaluating BV pacing after ablate and pace therapy. Late Breaking Clinical Trial, ACC Annual Scientific Sessions 2004
92. Laupacis A, Albers GW, Dalen JE, Dunn MI, Jacobson AK, Singer DE. Antithrombotic therapy in atrial fibrillation *Chest* 1998;114: 579S-589S
93. Murgatroyd RD, Gibson SM, Baiyan X. Double-blind placebo-controlled trial of digoxin in symptomatic paroxysmal atrial fibrillation. *Circulation* 1999;99:2765-70.

94. Hart RG, Benavente O, McBride R, Pearce LA. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. *Ann Intern Med* 1999; 131:492-501.
95. Antithrombotic Trialists' Collaboration. Collaboration meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction and stroke in high risk patients. *B Med J* 2002; 324: 71-86
96. Van Walraven C, Hart RG, Singer DE, Laupacis A, Connolly SJ, Petersen P, Koudstaal PJ, Chang, Hellemons B. Oral anticoagulants vs aspirin in non-valvular atrial fibrillation: an individual patient meta-analysis *JAMA* 2002 Nov20;288(19):2441-8.
97. Sudlow M, Thomson R, Thwaites B, Rodgers H, Kenny RA. Prevalence of atrial fibrillation and eligibility for anticoagulants in the community. *Lancet* 1998; 352:1167-71.) *Heart Fail* 2004 Jan; 6(1):109-15.
98. Klein AL, Grimm RA, Murray RD, Apperson-Hansen C, Asinger RW, Black IW, Davidoff R, Erbel R, Halperin JL, Orsinelli DA, Porter TR, Stoddard MF; Assessment of Cardioversion Using Transesophageal Echocardiography Investigators Use of transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation. *N Engl J Med*. 2001 May 10;344(19):1411-20
99. Pappone C, Rosanio S, Augello G, Gallus G, Vicedomini G, Mazzone P, Gulletta S, Gugliotta F, Pappone A, Santinelli V, Tortoriello V, Sala S, Zangrillo A, Crescenzi G, Benussi S, Alfieri O. Mortality, morbidity, and quality of life after circumferential pulmonary vein ablation for atrial fibrillation: outcomes from a controlled nonrandomized long-term study. *J Am Coll Cardiol*. 2003;42:185-97.
100. Li D, Fareh S, Leung TK, Nattel S. Promotion of atrial fibrillation by heart failure in dogs: atrial remodeling of a different sort. *Circulation*. 1999; 100:87-95.
101. Esaka Y, Yamane T, Takahashi A, Goya M, Kojima S, Soejima Y, Okamoto Y, Fujiwara H, Aonuma K, Nogami A, Hiroe M, Marumo F, Hiraoka M. Retrograde multiple and multifiber accessory pathway conduction in the Wolff-Parkinson-White syndrome: potential precipitating factor of atrial fibrillation *J Cardiovasc Electrophysiol*. 1998;9:141-51
102. Hwang C, Karagueuzian HS, Chen PS. Idiopathic paroxysmal atrial fibrillation induced by a focal discharge mechanism in the left superior pulmonary vein: possible roles of the ligament of Marshall. *J Cardiovasc Electrophysiol*. 1999; 10:636-48.

103. Wu TJ, Ong JJ, Chang CM, Doshi RN, Yashima M, Huang HL, Fishbein MC, Ting CT, Karagueuzian HS, Chen PS. Pulmonary veins and ligament of marshall as sources of rapid activations in a canine model of sustained atrial fibrillation *Circulation*. 2001;103:1157-63
104. Fitzpatrick AP, Kourouyan HD, Siu A, Lee RJ, Lesh MD, Epstein LM, Griffin JC, Scheinman MM. Quality of life and outcomes after radiofrequency His-bundle catheter ablation and permanent pacemaker implantation: impact of treatment in paroxysmal and established atrial fibrillation. *Am Heart J*. 1996; 131:499-507
105. Packer D, Johnson S. Origin of unablated discontinuities in linear lesions in the canine atrium. *J Am Coll Cardiol*. 1998; 31:254A (abs).
106. Jais P, Shah DC, Haissaguerre M, Takahashi A, Lavergne T, Hocini M, Garrigue S, Barold SS, Le Metayer P, Clementy J. Efficacy and safety of septal and left-atrial linear ablation for atrial fibrillation. *Am J Cardiol*. 1999;84:139R-146R
107. Khairy P, Chauvet P, Lehmann J, Lambert J, Macle L, Tanguay JF, Sirois MG, Santoianni D, Dubuc M. Lower incidence of thrombus formation with cryoenergy versus radiofrequency catheter ablation. *Circulation*. 2003;107:2045-50
108. Gerstenfeld EP, Guerra P, Sparks PB, Hattori K, Lesh MD. Clinical outcome after radiofrequency catheter ablation of focal atrial fibrillation triggers. *J Cardiovasc Electrophysiol*. 2001; 12:900-8.
109. Haissaguerre M, Jais P, Shah DC, Garrigue S, Takahashi A, Lavergne T, Hocini M, Peng JT, Roudaut R, Clementy J. Electrophysiological End Point for Catheter Ablation of Atrial Fibrillation Initiated From Multiple Pulmonary Venous Foci. *Circulation*. 2000; 101:1409-1417.
110. Sohn RH, Schiller NB. Left upper pulmonary vein stenosis 2 months after radiofrequency catheter ablation of atrial fibrillation. *Circulation*. 2000; 101:E154-5.
111. Hocini M, Haissaguerre M, Shah D, Jais P, Peng JT, Yamane T, Deisenhofer I, Garrigue S, Fuimaono K, Pike R, Clementy J. Multiple sources initiating atrial Fibrillation from a single pulmonary vein identified by a circumferential catheter. *Pacing Clin Electrophysiol*. 2000; 23:1828-31.
112. Martin RE, Ellenbogen KA, Lau YR, Hall JA, Kay GN, Shepard RK, Nixon JV, Wood MA. Phased-array intracardiac echocardiography during pulmonary vein isolation and linear ablation for atrial fibrillation. *J Cardiovasc Electrophysiol* 2002;13:873-9.

113. Pappone C, Oreto G, Rosanio S, Vicedomini G, Tocchi M, Gugliotta F, Salvati A, Dicandia C, Calabro MP, Mazzone P, Ficarra E, Di Gioia C, Gulletta S, Nardi S, Santinelli V, Benussi S, Alfieri O. Atrial electroanatomic remodeling after Circumferential radiofrequency pulmonary vein ablation: efficacy of an anatomic Approach in a large cohort of patients with atrial fibrillation. *Circulation*. 2001; 104:2539-44
114. WC Sealy, JJ Gallagher, and J Kasell. His bundle interruption for control of inappropriate ventricular responses to atrial arrhythmias. *Ann. Thorac. Surg.*, Jul 1981; 32: 429 - 438.
115. Scheinman MM, Morady F, Hess DS: Catheter-induced ablation of the atrioventricular junction to control refractory supraventricular arrhythmias. *J Am Med Assoc* 982;248:851.
116. Sueda T., Nagata T., Shikata H. Simple left atrial procedure for chronic atrial fibrillation associated with mitral valve disease. *Ann Thorac Surg* 1996; 62:1796-1800.
117. Cox JL. Atrial fibrillation I: a new classification system. *J. Thorac. Cardiovasc. Surg.* 2003; 126:1686-1692.
118. Gosselink ATM, Crijns HJGM, Hamer HPM, Hillege H, Lie KI. Changes in left and right atrial size after cardioversion of atrial Atrial fibrillation: role of mitral valve disease. *J Am Coll Cardiol* 1993; 22:1666-1672.
119. Obadia JF, El Farra M, Bastien OH, Lievre M, Martelloni Y, Chassignolle JF. Outcome of atrial Atrial fibrillation after mitral valve repair. *J Thorac Cardiovasc Surg* 1997; 114:179-185.
120. Jessurun E.R., van Hemel N.M., Kelder J.C., et al. Mitral valve surgery and atrial Fibrillation: is atrial fibrillation surgery also needed? *Eur J Cardio- thorac Surg* 2000; 17:530-537
121. Prasad SM, Maniar HS, Camillo CJ, Schuessler RB, Boineau JP, Sundt III TM, III, Cox JL, Damiano RJ. The Cox maze III procedure for atrial fibrillation: long-term efficacy in patients undergoing lone versus concomitant procedures *J Thorac Cardiovasc Surg* 2003; 126:1822-1827.
122. Bando K, Kobayashi J, Kosakai Y, Hirata H, Sasako Y, Nakatani S, Yagihara T, Kitamura S. Impact of Cox maze procedure on outcome in patients with atrial fibrillation and mitral valve disease. *J Thorac Cardiovasc Surg* 2002; 124:575-583

123. Raman J, Ishikawa S, Storer MM, Power JM. Surgical radiofrequency ablation of both atria for atrial fibrillation: results of a multicenter trial. *J Thorac Cardiovasc Surg* 2003; 126:1357-1365
124. Johnson WD, Ganjoo AK, Stone CD. The left atrial appendage: our most lethal Human attachment! Surgical implications. *Eur J Cardiothorac Surg.* 2000; 17:718–722.
125. Garcia-Fernandez M, Perez-David E, Quiles J, Peralta J, Garcia-Rojas I, Bermejo J, Moreno M, Silva J. Role of the left atrial appendage obliteration in stroke Reduction in patients with mitral valve prosthesis. A transesophageal echocardiographic study. *A Amer Coll Cardiol* 2003; 42:12-53-1258.
126. Cox JL. Atrial fibrillation II. Rationale for surgical treatment. *J Thorac Cardiovasc Surg* 2003; 126:1693-1699
127. Mohr FW, Fabricius A, Falk V, et al. Curative treatment of atrial fibrillation: acute and Mid-term results of intraoperative radiofrequency ablation of atrial Fibrillation. *J Thorac Cardiovasc Surg* 2002; 123:919–27.
128. Benussi S, Nascimbene S, Agricola E, Calori G, Calvi S, Caldarola A, Oppizzi M, Casati V, Pappone C, Alfieri O. Surgical ablation of atrial fibrillation using the epicardial radiofrequency approach: mid-term results and risk analysis. *Ann. Thorac. Surg.* 2002; 74:1050-1057.
129. Doll N, Borger MA, Fabricius F, Stephan S, Gummert J, Mohr FW, Hauss J, Kottkamp H, Hindricks G. Esophageal perforation during left atrial radiofrequency ablation: Is the risk too high? *J. Thorac. Cardiovasc. Surg.* 2003; 125:836-842.
130. Saltman AE, Rosenthal LS, Francalancia NA, Lahey SJ. A completely endoscopic Approach to microwave ablation for atrial fibrillation. *Heart Surg Forum.* 2003; 6(3):E38-41.
131. Gillis AM, Morck M. Atrial fibrillation following DDDR pacemaker implantation *J Cardiovasc Electrophysiol* 2002; 13:542-547.
132. Willems R, Gillis AM. New Indications for Pacing. *Curr Cardiol Rep* 2003 Sep; 5(5):369-74.
133. Sweeney MO, Hellkamp AS, Ellenbogen KA, Greenspon AJ, Freedman RA, Lee KL, Lamas GA; Mode Selection Trial Investigators. Adverse effect of ventricular Pacing on heart failure and atrial fibrillation among patients with normal baseline QRS duration in

- a clinical trial of pacemaker therapy for sinus node dysfunction. *Circulation*. 2003; 107:2932-7.
134. Kerr CR, Connolly S, Abdollah H, Roberts RS, Gent M, Yusuf S, Gillis AM, Tang ASL, Talajic M, Klein G, Newman D.. Effect of pacing mode on cardiovascular death and stroke. The Canadian Trial of Physiologic Pacing: Effects of physiologic pacing during long Term Follow-up. *Circulation* 2004; 109: 357 – 362.
 135. Lamas GA, Lee KL, Sweeney MO, Silverman R, Leon A, Yee R, Marinchak RA, Flaker G, Schron E, Orav EJ, Hellkamp AS, Greer S, McAnulty J, Ellenbogen K, Ehlert F, Freedman RA, Estes NA 3rd, Greenspon A, Goldman L. Ventricular pacing or dualchamber pacing for sinus-node dysfunction. *N Engl J Med*. 2002; 346:1854-62.
 136. Connolly SJ, Kerr CR, Gent M, Roberts RS, Yusef S, Gillis AM, Sami MH, Talajic M, Tang AS, Klein GJ, Lau C and Newman DM for the CTOPP Investigators. Effects of physiologic pacing versus ventricular pacing on the risk of stroke and death due to cardiovascular causes. *N Engl J Med* 2000; 342:1385-91.
 137. Prakash A, Delfaut P, Krol RB, Saksena S. Regional right and left atrial activation patterns during single- and dual-site atrial pacing in patients with atrial fibrillation *Am J Cardiol*. 1998; 82:1197-204.
 138. Crystal E, Connolly SJ, Sleik K, Ginger TJ, Yusuf S. Interventions on prevention of Postoperative atrial fibrillation in patients undergoing heart surgery: a meta-analysis. *Circulation* 2002; 106:75-80.
 139. Bailin SJ, Adler S, Giudici M. Prevention of chronic atrial fibrillation by pacing in the region of Bachmann's bundle: results of a multicenter randomized trial. *J Cardiovasc Electrophysiol* 2001; 12:912-7.
 140. Padeletti L, Porciani MC, Michelucci A, Colella A, Ticci P, Vena S, Costoli A, Ciapetti C, Pieragnoli P, Gensini GF. Interatrial septum pacing: a new approach to prevent recurrent atrial fibrillation. *J Interv Card Electrophysiol* 1999; 3:35-43.
 141. Saksena S, Prakash A, Ziegler P, Hummel JD, Friedman P, Plumb VJ, Wyse DG, Johnson E, Fitts S, Mehra R. Improved suppression of recurrent atrial fibrillation with dual-site right atrial pacing and antiarrhythmic drug therapy. *J Am Coll Cardiol* 2002; 40:1140-50.
 142. D'Allonnes GR, Pavin D, Leclercq C, Ecke JE, Jauvert G, Mabo P, Daubert JC. Long-term effects of biatrial synchronous pacing to prevent drug-refractory atrial tachyarrhythmia: a nine-year experience. *J Cardiovasc Electrophysiol* 2000; 11:1081-91.

143. Pappone C, Santinelli V, Manguso F. A randomized study of prophylactic Catheter ablation in asymptomatic patients with the Wolff-Parkinson- White Syndrome. *N Engl J Med* 2003; 349:1803-11.
144. Odd DM, Klein GJ, Krahn AD, Skanes AC, Yee R. Asymptomatic Wolff- Parkinson-White syndrome: is it time to revisit guidelines? *J Am Coll Cardiol* 2003; 41:245-8.
145. Appone C, Santinelli V, Rosanio S. Usefulness of invasive electrophysiologic testing to stratify the risk of arrhythmic events in Asymptomatic patients with Wolff-Parkinson-White pattern: results from a large prospective long-term follow-up study. *J Am Coll Cardiol* 2003; 41:239-44.
146. Fuster V, Ryden LE, Asinger RW. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary. A Report of The American College of Cardiology/ American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients with Atrial Fibrillation): developed in Collaboration with the North American Society of Pacing and Electrophysiology. *J Am Coll Cardiol* 2001; 38:1231-66.
147. Bartalena L, Bogazzi F, Braverman LE, Martino E. Effects of amiodarone administration during pregnancy on neonatal thyroid function and subsequent neurodevelopment. *J Endocrinol Invest* 2001; 24:116-30.
148. Ginsberg JS, Greer I, Hirsh J. Use of antithrombotic agents during pregnancy. *Chest* 2001; 119:122S-131S.
149. Silversides CK, Colman JM, Sermer M, Siu SC. Cardiac risk in pregnant women with rheumatic mitral stenosis. *Am J Cardiol* 2003; 91:1382-5.
150. Muller GI, Deal BJ, Strasburger JF, Benson DW, Jr. Electrocardiographic features Of atrial tachycardias after operation for congenital heart disease. *Am J Cardiol* 1993; 71:122-4.
151. Odegard KC, McGowan FX, Jr., Zurakowski D et al. Procoagulant and anticoagulant factor abnormalities following the Fontan procedure: increased factor VIII may predispose to thrombosis. *J Thorac Cardiovasc Surg* 2003; 125:1260-7
152. Blomstrom-Lundqvist C, Scheinman MM, Aliot EM et al. ACC/AHA/ESC guidelines For the management of patients with supraventricular arrhythmias-- executive Summary: a report of the

- American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines(Writing Committee to Develop Guidelines for the Management of Patients with Supraventricular Arrhythmias). *Circulation* 2003; 108:1871-909.
153. Beaufort-Krol GC, Bink-Boelkens MT. Effectiveness of sotalol for atrial flutter in Children after surgery for congenital heart disease. *Am J Cardiol* 1997; 79:92-4.
 154. Stephenson EA, Casavant D, Tuzi J. Efficacy of atrial antitachycardia pacing using the Medtronic AT500 pacemaker in patients with congenital heart disease. *Am J Cardiol* 2003; 92:871-6.
 155. Chiu CC, McCrindle BW, Hamilton RM, Griffiths JE, Gow RM. Clinical use of permanent pacemaker for conversion of intraatrial reentry tachycardia in children. *Pacing Clin Electrophysiol* 2001; 24:950-6.
 156. Collins KK, Love BA, Walsh EP, Saul JP, Epstein MR, Triedman JK. Location of Acutely successful radiofrequency catheter ablation of intraatrial reentrant Tachycardia in patients with congenital heart disease. *Am J Cardiol* 2000;86:969-74.
 157. de Groot NM, Schalij MJ, Zeppenfeld K, Blom NA, Van der Velde ET, Van der Wall EE. Voltage and activation mapping: how the recording technique affects the outcome of catheter ablation procedures in patients with congenital heart disease. *Circulation* 2003; 108:2099-106.
 158. Triedman JK, Alexander ME, Love BA et al. Influence of patient factors and ablative technologies on outcomes of radiofrequency ablation of intra-atrial reentrant tachycardia in patients with congenital heart disease. *J Am Coll Cardiol*2002; 39:1827-35.
 159. Vignati G, Crupi G, Vanini V, Iorio FS, Borghi A, Giusti S. Surgical treatment of arrhythmias related to congenital heart diseases. *Ann Thorac Surg* 2003; 75:1194-9.
 160. Oussama M Wazni, David O. Marton 2005
 161. Psychari SN, Apotolou TS ,Hamodraka E ,Liakor G, Kremastinos DT. , *Am J Cardiol* 2005;95:764-767
 162. Korantzopoulos P, Kolettis T, Kountouris E, Siogask , *Eur Heart J* 2004; 25:1086
 163. Calol, Bian conil , colivicchi F, Lamberti F, n3 F.A for prevention of A.F after CABG ,*JA-coll cardiol* 2005; 45:1723-1728

164. Boriani G, Martigan C, 2002
165. CHEST, August ,1995 by Giuseppe Boriani, Alessandro Capucci, Tiziano Lenzi, Mario Sanguinetti, Bruno Magnani
166. Giuseppe Boriani, Maura Biffi ; Conversion of recent onset atrial fibrillation to sinus rhythm :Effect of different Drug protocols Pacing & Clinical electrophysiology 21(11), 2470-2474.doi:10.1111/j.1540-8159.1998.tb01203.x
167. Kerin NZ ,Faitel K , Naini M. the efficacy of IV amiodarone for conversion of A.F Arch Intern Med 1996;156:49-53
168. Teleman RG, Gosselink AT,Crijns HJ. Efficacy, Safety &determination of conversion of A.F with amiodarone. Am J cardiol 1997;20:337-340
169. Cotter G , Blatt A, Kluski E, et al .conversion of recent A.F to sinus rhythm ,effect of no treatment & high dose amiodarone . A randomized, placebo controlled study. Eur Heart J 1999; 20:1833-1842
170. Circulation 2002; Julie B. shea & William H Maisel.
171. Dell Orfano JT, Patel H, Wolbrette DL, Luck JC, Naccarelli GV. Acute treatment of atrial fibrillation: spontaneous conversion rates & cost of care.Am J Cardiol 1999; 83:788-790